<DOC>
	<DOCNO>NCT00985673</DOCNO>
	<brief_summary>The purpose study characterize safety immunogenicity H1N1 ( swine ) flu vaccine GSK2340274A GSK2340273A co-administered seasonal flu vaccine adult 19 40 year age .</brief_summary>
	<brief_title>Safety Immunogenicity H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine Adults</brief_title>
	<detailed_description>Collaborators : United States Department Health Human Services , Office Biomedical Advanced Research Development Authority</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Male female adult , 1940 year age time first vaccination . Safety laboratory test result within parameter specify protocol . Satisfactory baseline medical assessment physical examination . Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit document signature inform consent document . Access consistent mean telephone contact , may either home workplace , land line , mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day first vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Previous vaccination H1N1vlike virus vaccine medical history physicianconfirmed infection H1N1vlike virus . Prior receipt time seasonal influenza vaccine . Planned administration vaccine foreseen study protocol Day 0 Day 63 phlebotomy . Administration license vaccine within 4 week first study vaccine dose . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Receipt systemic glucocorticoid within one month prior study enrolment , cytotoxic immunosuppressive drug within six month study enrolment . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Receipt immunoglobulins and/or blood product within three month study enrolment plan administration product study period . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence temperature &gt; = 38.0ºC ( &gt; =100.4ºF ) , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within six week receipt seasonal influenza vaccine . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin test result prior first vaccination . Lactating nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
	<keyword>influenza infection</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340273A</keyword>
</DOC>